| 効果 | なし |
| 試験方法 | メタ分析法 |
| 試験期間 | 不明 |
| 被験者数 | 7 |
| 性別 | 不明 |
A meta-analysis on chromium in type II diabetics where supplementation lasted for over three months noted that, relative to placebo, there was a mild but significant reduction in blood glucose. HbA1c and all biomarkers of lipid metabolism, as well as weight, were all unaffected.
This meta-analysis was restricted to type II diabetics and the duration of at least three months, but at times included studies containing chromium enriched yeast and biotin supplementation alongside the chromium.
Beneficial Effect Of Chromium Supplementation On Glucose, HbA1C And Lipid Variables In Individuals With Newly Onset Type-2 Diabetes
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 40 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満 |
Supplementation of brewers yeast (conferring 42 μg chromium) in newly diagnosed diabetics for three months was able to significantly reduce blood glucose (47.6%), HbA1c (from 9.5% to 6.8%), and systolic blood pressure (12%) while causing some benefit to all lipid parameters except vLDL and HDL relative to placebo.
Chromium Picolinate Does Not Improve Key Features Of Metabolic Syndrome In Obese Nondiabetic Adults
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 60 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満 |
Chromium supplementation at 1,000mcg daily (as picolinate) increased the acute insulin response to glucose but failed to influence any other measured parameter of metabolic syndrome after 16 weeks supplementation in adults with signs of metabolic syndrome yet no diagnosed diabetes.
Chromium Supplementation And The Effects On Metabolic Status In Women With Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
| 効果 | 減少 |
| 数値 | -2.5 vs. +3.0 mg/d, in the chromium vs. placebo groups, respectively. p = 0.05 |
| 試験方法 | ランダム化比較試験 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 64 |
| 性別 | 女性 |
| 年齢 | 18-29 |
| 体型 | 肥満, 平均 |
64 women with polycystic ovarian syndrome were randomized to receive 200 µg chromium picolinate or placebo for 8 weeks, and measures of insulin sensitivity and blood lipids were measured. Insulin sensitivity improved, and blood lipid profile trended toward significance.